Active Pharmaceutical Ingredient Market by type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, diabetes, Orthopedic, CNS, Nephrology, Ophthalmology) - Global Forecast to 2020

Date: October 28, 2015
Pages: 208
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GFEBC7D7223EN
Leaflet:

Download PDF Leaflet

Active Pharmaceutical Ingredient Market by type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, diabetes, Orthopedic, CNS, Nephrology, Ophthalmology) - Global Forecast to 2020
The Active Pharmaceutical Ingredients market is categorized on the basis of type, type of manufacturer, type of synthesis, therapeutic area and region. Factors such as increasing incidence of life style and age related diseases, Increasing prevalence of cancer across the world, Technological advancements in the APIs Manufacturing, Emerging markets for biosimilars and increasing scope for Highly potent active ingredients are driving market growth. On the other hand, stringent regulatory guidelines and global economic recession may restrict market growth in the forecast period.

North America accounts for the highest share of the global APIs market. The overall technological advancements in this region coupled with factors like increase in lifestyle and age related disorders in this region, the increase in demand for specialty biological and specialty drugs and increasing government focus on generics following the implementation of the Patient Protection and Affordable Care Act is driving the growth of this market.

Apart from the comprehensive geographical analysis, product analysis, and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise basic views on key players and their product portfolios, developments, and strategies adopted. The abovementioned market research data, current market sizes, and forecast of future trends will help key players and new entrants make informed decisions regarding product offerings, geographical focus, and change in strategic approach; R&D investments; and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
  • Market Penetration: Comprehensive information on the product portfolios of top players in the APIs market. The report analyzes the APIs and HPAPIs market by type, type of synthesis, type of manufacturer, therapeutic area and region.
  • Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and new product launches in the APIs marketo Competitive Assessment: In-depth assessment of market strategies, geographical and business segments, and product portfolios of the leading players in APIs market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for APIs across geographies
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the APIs market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 LIMITATIONS
1.5 CURRENCY
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
  2.1.1 SECONDARY RESEARCH
    2.1.1.1 Key data from secondary sources
  2.1.2 PRIMARY RESEARCH
    2.1.2.1 Key data from primary sources
    2.1.2.2 Key industry insights
    2.1.2.3 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
  2.2.1 BOTTOM-UP APPROACH
  2.2.2 TOP DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
  2.4.1 ASSUMPTIONS
  2.4.2 LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
4.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC AREA
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS
4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
4.5 GEOGRAPHIC SNAPSHOT OF THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
4.6 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
4.7 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS
4.8 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
4.9 GEOGRAPHIC SNAPSHOT OF THE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
  5.2.1 BY TYPE
  5.2.2 MARKET SEGMENTATION, BY TYPE OF SYNTHESIS
  5.2.3 MARKET SEGMENTATION, BY TYPE OF MANUFACTURER
  5.2.4 MARKET SEGMENTATION, BY THERAPEUTIC AREA
  5.2.5 MARKET SEGMENTATION, BY REGION
5.3 MARKET DYNAMICS
  5.3.1 DRIVERS
    5.3.1.1 Increasing incidence of lifestyle and age-related diseases
    5.3.1.2 Rising cancer prevalence across the globe
    5.3.1.3 Technological advancements in API manufacturing
  5.3.2 RESTRAINTS
    5.3.2.1 Stringent regulatory requirements
    5.3.2.2 Economic recession
  5.3.3 OPPORTUNITIES
    5.3.3.1 Emerging biosimilars market
    5.3.3.2 Increasing scope for highly potent active pharmaceutical ingredients
  5.3.4 CHALLENGES
    5.3.4.1 Product differentiation - A major concern for API manufacturers

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY SYNTHESIS

  6.1.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
  6.1.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE
    6.1.2.1 Innovative Synthetic APIs
    6.1.2.2 Generic Synthetic APIs
  6.1.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
    6.1.3.1 Biotech APIs Market, by Product
      6.1.3.1.1 Monoclonal Antibodies
      6.1.3.1.2 Recombinant Proteins
      6.1.3.1.3 Vaccines
    6.1.3.2 Biotech APIs Market, by Type
      6.1.3.2.1 Innovative Biotech APIs
      6.1.3.2.2 Biogenerics/Biosimilars

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER

7.1 INTRODUCTION
7.2 CAPTIVE API MANUFACTURERS
7.3 MERCHANT API MANUFACTURERS
  7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE
    7.3.1.1 Innovative APIs
    7.3.1.2 Generic APIs

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

8.1 INTRODUCTION
8.2 INNOVATIVE APIS SEGMENT
8.3 GENERIC APIS SEGMENT

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC AREA

9.1 ONCOLOGY
9.2 DIABETES
9.3 CARDIOVASCULAR DISEASE
9.4 CNS AND NEUROLOGICAL DISORDERS
9.5 ORTHOPEDIC DISORDERS
9.6 NEPHROLOGY
9.7 OPHTHALMOLOGY
9.8 PULMONOLOGY
9.9 GASTROINTESTINAL DISORDERS
9.10 ENDOCRINOLOGY

10 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

10.1 INTRODUCTION
  10.1.1 HPAPI CLASSIFICATION
  10.1.2 OVERVIEW: HPAPI GLOBAL MARKET
  10.1.3 MANUFACTURING CAPABILITIES
    10.1.3.1 Handling requirements
    10.1.3.2 Personnel considerations
    10.1.3.3 Plant and equipment
    10.1.3.4 Technology
10.2 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
  10.2.1 HPAPI MARKET, BY TYPE
    10.2.1.1 INNOVATIVE HPAPI
    10.2.1.2 GENERIC HPAPI
10.3 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER
    10.3.1.1 CAPTIVE HPAPI SECTOR
    10.3.1.2 MERCHANT HPAPI SECTOR
10.4 HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY METHOD OF SYNTHESIS

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

11.1 INTRODUCTION
11.2 PEST ANALYSIS
  11.2.1 POLITICAL FACTORS
  11.2.2 ECONOMICAL FACTORS
  11.2.3 SOCIAL FACTORS
  11.2.4 TECHNOLOGICAL FACTORS
11.3 NORTH AMERICA
  11.3.1 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.3.2 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.3.3 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.3.4 U.S.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.3.5 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.3.6 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
11.4 EUROPE
  11.4.1 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.2 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.3 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.4 U.K.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.5 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.6 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.7 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.8 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.9 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.10 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.11 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.12 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.13 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.4.14 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
11.5 ASIA
  11.5.1 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.2 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.3 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.4 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.5 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.6 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.7 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.8 SOUTH KOREA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.9 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.10 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.11 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.5.12 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
11.6 ROW
  11.6.1 ROW: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  11.6.2 ROW: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

12 COMPETITIVE LANDSCAPE

12.1 COMPETITIVE SITUATION AND TRENDS
  12.1.1 NEW PRODUCT LAUNCHES
  12.1.2 MERGERS AND ACQUISITIONS
  12.1.3 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS, AND JOINT VENTURES
  12.1.4 EXPANSION

13 COMPANY PROFILES

(Overview, Financials, Products & Services, Strategy, & Developments)*

13.1 INTRODUCTION
13.2 TEVA PHARMACEUTICAL INDUSTRIES LIMITED
13.3 DR. REDDY’S LABORATORIES LTD.
13.4 SUN PHARMACEUTICAL INDUSTRIES LTD.
13.5 AUROBINDO PHARMA LTD.
13.6 NOVARTIS INTERNATIONAL AG
13.7 ALBEMARLE CORPORATION
13.8 SIGMA-ALDRICH CORPORATION
13.9 MYLAN INC.
13.10 ALLERGAN PLC
13.11 BOEHRINGER INGELHEIM

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

14 APPENDIX

14.1 INSIGHTS FROM INDUSTRY EXPERTS
14.2 DISCUSSION GUIDE
14.3 OTHER DEVELOPMENTS, BY COMPANY, 2012-2015
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
14.5 AVAILABLE CUSTOMIZATIONS
14.6 RELATED REPORTS

LIST OF TABLES

Table 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013–2020 (USD BILLION)
Table 2 GLOBAL SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)
Table 3 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013–2020 (USD BILLION)
Table 4 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013–2020 (USD BILLION)
Table 5 ASIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)
Table 6 GLOBAL SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013–2020 (USD BILLION)
Table 7 GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)
Table 8 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013–2020 (USD BILLION)
Table 9 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013–2020 (USD BILLION)
Table 10 ASIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013–2020 (USD BILLION)
Table 11 GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013–2020 (USD BILLION)
Table 12 GLOBAL BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013–2020 (USD BILLION)
Table 13 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2013–2020 (USD BILLION)
Table 14 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY REGION, 2013–2020 (USD BILLION)
Table 15 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013–2020 (USD BILLION)
Table 16 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013–2020 (USD BILLION)
Table 17 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR CAPTIVE MANUFACTURERS, BY COUNTRY, 2013–2020 (USD BILLION)
Table 18 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY REGION, 2013–2020 (USD BILLION)
Table 19 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013–2020 (USD BILLION)
Table 20 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013–2020 (USD BILLION)
Table 21 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY COUNTRY, 2013–2020 (USD BILLION)
Table 22 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE FOR MERCHANT MANUFACTURERS, BY TYPE, 2013–2020 (USD BILLION)
Table 23 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 24 PATENTS EXPIRIES, 2015
Table 25 GLOBAL GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC AREA, 2013–2020 (USD BILLION)
Table 27 CANCER: ESTIMATED INCIDENCE, MORTALITY, AND PREVALENCE (2012)
Table 28 REGIONAL ESTIMATES FOR DIABETES (2013)
Table 29 U.S.: LEADING RESPIRATORY DRUGS, 2014
Table 30 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 31 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 32 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 33 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 34 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 35 GLOBAL GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 36 NORTH AMERICA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 37 EUROPE: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 38 ASIA: GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 39 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF MANUFACTURER, 2013-2020 (USD BILLION)
Table 40 GLOBAL CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 41 NORTH AMERICA: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 42 EUROPE: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 43 ASIA: CAPTIVE HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 44 GLOBAL MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 45 NORTH AMERICA: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 46 EUROPE: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 47 ASIA: MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 48 GLOBAL MERCHANT HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 49 GLOBAL HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 50 GLOBAL SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 51 NORTH AMERICA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 52 EUROPE: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 53 ASIA: SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 54 GLOBAL SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 55 GLOBAL BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 56 NORTH AMERICA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 57 EUROPE: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 58 ASIA: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 59 GLOBAL BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 60 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2013-2020 (USD BILLION)
Table 61 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 62 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 63 ASIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD BILLION)
Table 64 NORTH AMERICA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 65 U.S.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 66 U.S.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 67 U.S.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 68 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 69 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 70 CANADA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 71 EUROPE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 72 U.K.: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 73 U.K.: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 74 U.K.: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 75 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 76 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 77 FRANCE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 78 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 79 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 80 GERMANY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 81 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 82 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 83 SPAIN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 84 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 85 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 86 ITALY: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 87 ROE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 88 ROE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 89 ROE: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 90 ASIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 91 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 92 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 93 INDIA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 94 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 95 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 96 JAPAN: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 97 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 98 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 99 SOUTH KOREA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 100 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 101 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 102 CHINA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 103 ROA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2013-2020 (USD BILLION)
Table 104 ROA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 105 ROA: HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE OF SYNTHESIS, 2013-2020 (USD BILLION)
Table 106 ROW: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 107 ROW: BIOTECH HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PRODUCT, 2013-2020 (USD BILLION)
Table 108 NEW PRODUCT LAUNCHES
Table 109 MERGERS AND ACQUISITIONS
Table 110 PARTNERSHIPS, AGREEMENTS, COLLABORATIONS, AND JOINT VENTURES
Table 111 EXPANSIONS
Table 112 SUN PHARMACEUTICALS INDUSTRIES LTD.
Table 113 TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Table 114 DR. REDDY’S LABORATORIES
Table 115 AUROBINDO PHARMA
Table 116 NOVARTIS
Table 117 BOEHRINGER INGELHEIM
Table 118 ALBEMARLE CORPORATION
Table 119 SIGMA-ALDRICH
Table 120 MYLAN INC.
Table 121 ALLERGAN PLC.

LIST OF FIGURES

Figure 1 GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
Figure 2 RESEARCH DESIGN
Figure 3 BOTTOM-UP APPROACH
Figure 4 TOP-DOWN APPROACH
Figure 5 DATA TRIANGULATION METHODOLOGY
Figure 6 API MARKET, BY TYPE (2015 VS. 2020): THE INNOVATIVE API SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD
Figure 7 CAPTIVE MANUFACTURERS SEGMENT TO HOLD LARGEST MARKET SIZE IN 2015
Figure 8 SYNTHETIC APIS SEGMENT TO COMMAND LARGEST MARKET SIZE IN 2015
Figure 9 ONCOLOGY SEGMENT TO FORM LARGEST MARKET SHARE IN 2015
Figure 10 API MARKET, BY REGION: NORTH AMERICA TO COMMAND LARGEST SHARE IN 2015
Figure 11 HPAPI MARKET, BY TYPE (2015 VS. 2020): THE INNOVATIVE HPAPI SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD
Figure 12 HPAPI MARKET, BY TYPE OF MANUFACTURER (2015 VS. 2020): THE CAPTIVE APIS SEGMENT TO DOMINATE MARKET IN THE FORECAST PERIOD
Figure 13 HPAPI MARKET, BY MODE OF SYNTHESIS (2015 VS. 2020): SYNTHETIC APIS TO DOMINATE MARKET IN THE FORECAST PERIOD
Figure 14 HPAPI MARKET, BY REGION: NORTH AMERICA TO COMMAND LARGEST SHARE IN 2015
Figure 15 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS OFFER HIGH GROWTH OPPORTUNITIES
Figure 16 THE ONCOLOGY SEGMENT TO ACCOUNT FOR THE LARGEST SIZE OF THE MARKET (2015–2020)
Figure 17 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS TO COMMAND THE LARGEST SHARE IN 2015
Figure 18 MERCHANT MANUFACTURERS SEGMENT TO GROW AT THE HIGHEST RATE FROM 2015 TO 2020
Figure 19 THE ASIAN REGION TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD
Figure 20 GENERIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS OFFER HIGH GROWTH OPPORTUNITIES
Figure 21 SYNTHETIC HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS TO COMMAND THE LARGEST SHARE IN 2015
Figure 22 THE MERCHANT MANUFACTURERS SEGMENT TO GROW AT THE HIGHEST RATE FROM 2015 TO 2020
Figure 23 ASIA TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
Figure 24 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY TYPE
Figure 25 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY TYPE OF SYNTHESIS
Figure 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY TYPE OF MANUFACTURER
Figure 27 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY THERAPEUTIC AREA
Figure 28 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION, BY REGION
Figure 29 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 30 SYNTHETIC CHEMICAL ACTIVE PHARMACEUTICAL INGREDIENTS TO DOMINATE THE GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015–2020)
Figure 31 NORTH AMERICA IS THE LARGEST SEGMENT OF THE GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015–2020)
Figure 32 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS TO WITNESS HIGHEST GROWTH IN THE FORECAST PERIOD (2015–2020)
Figure 33 RECOMBINANT PROTEINS TO DOMINATE THE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015–2020)
Figure 34 NORTH AMERICA TO FORM THE LARGEST SEGMENT OF THE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD (2015–2020)
Figure 35 THE MERCHANT API MANUFACTURERS SEGMENT TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES IN THE FORECAST PERIOD
Figure 36 CAPTIVE API MANUFACTURERS MARKET, BY REGION: ROW TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 37 MERCHANT API MANUFACTURERS MARKET, BY REGION: ASIA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
Figure 38 GENERIC APIS TO WITNESS HIGHER GROWTH RATE
Figure 39 GENERIC ACTIVE PHARMACEUTICALS MARKET, BY REGION: ASIA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD (2015–2020)
Figure 40 ONCOLOGY TO DOMINATE THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET IN THE FORECAST PERIOD
Figure 41 NORTH AMERICAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
Figure 42 EUROPEAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
Figure 43 KEY PLAYERS MAJORLY ADOPTED INORGANIC GROWTH STRATEGIES BETWEEN 2012 AND 2015
Figure 44 MARKET EVOLUTION FRAMEWORK –2014 WAS THE MOST ACTIVE YEAR DURING THE STUDIED PERIOD
Figure 45 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS BETWEEN 2012 AND 2015
Figure 46 GEOGRAPHIC REVENUE MIX FOR THE TOP 5 PLAYERS IN THE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
Figure 47 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
Figure 48 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
Figure 49 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
Figure 50 AUROBINDO PHARMA LTD.: COMPANY SNAPSHOT
Figure 51 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT
Figure 52 ALBEMARLE CORPORATION: COMPANY SNAPSHOT
Figure 53 SIGMA-ALDRICH CORPORATION: COMPANY SNAPSHOT
Figure 54 MYLAN INC.: COMPANY SNAPSHOT
Figure 55 ALLERGAN PLC.: COMPANY SNAPSHOT
Figure 56 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
Skip to top


Ask Your Question

Active Pharmaceutical Ingredient Market by type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, diabetes, Orthopedic, CNS, Nephrology, Ophthalmology) - Global Forecast to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: